The abstract is read at the publisher; the summary is JClub's.
SilencioMA, a single silencing compound targeting MAPT and APP mRNAs, reduces Aβ and tau pathology after one intracerebroventricular dose in 5XFAD/PS19 mice.
- Why it matters: Disease-modifying therapies that hit both amyloid-beta and pathological tau are expected to have greater impact than single-target approaches, but dual-target DMTs remain challenging.
- What they did: The authors developed SilencioMA using silencing connected interfering oligonucleotides against MAPT and APP, testing cerebrospinal fluid delivery after a single intracerebroventricular injection in 5XFAD/PS19 mice.
- The result: CSF administration lowers Aβ and tau and associated pathology in this severe amyloidosis and tauopathy model, supporting dual Aβ/tau targeting as a proof-of-concept platform for further development.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.